



# Genetics-inspired Therapeutics for Pulmonary Hypertension

A PVRI Symposium

2 June 2026

Royal College of Physicians, London



# Programme

---

08:00 - 09:00      **Registration and refreshments**

---

09:00 - 09:05      **Welcome**  
Brad Maron, University of Maryland

## **Genetic insights into pulmonary vascular disease**

Chairs: Stefan Graf, University of Cambridge and Micheala Aldred, Indiana University

09:05 - 09:35      **Overview of genetics in PH & hereditary  
haemorrhagic telangiectasia**  
Richard Trembath, King's College London

09:35 - 09:50      **Genetics of the right ventricle**  
Lars Harbaum, Universitätsklinikum Hamburg-Eppendorf

09:50 - 10:05      **Q&A**

## **Therapeutic agents targeting TGF- $\beta$ /BMP pathway: Part 1**

Chairs: Brad Maron, University of Maryland & Luke Howard, Imperial College Healthcare NHS Trust

10:05 - 10:25      **Overview of TGF $\beta$ -BMP pathway**  
Marie-Jose Goumans, Leiden University

10:25 - 10:45      **Biology behind the PAH – HHT overlap**  
Wei Li, University Of Cambridge

---

10:45 - 11:15      **Refreshment break**

---

11:15 - 11:35      **Sotatercept – overview of clinical experience**  
Ardeschir Ghofrani, Justus-Liebig-Universität Gießen

11:35 - 11:55      **Restoring Right Ventricular Function Through  
Activin Modulation**  
Simon Gibbs, Imperial College London

11:55 - 12:15      **Sotatercept – deep phenotyping the cardiac  
response**  
Khodr Tello, Justus-Liebig-Universität Gießen

12:15 - 12:30      **Discussion**

---

12:30 - 13:30      **Buffet lunch**

---

## **Therapeutic agents targeting TGF- $\beta$ /BMP pathway: Part 2**

Chairs: Jane Leopold, Harvard University and Nick Morrell, University of Cambridge

13:30 - 13:50      **Sotatercept – what can we learn from the biological response**

Paul Yu, Mass General Brigham

13:50 - 14:10      **Inhibiting BMP9**

Kevin Hart, Pfizer

14:10 - 14:30      **LTP001 study**

Alex Rothman, The University of Sheffield and Ana-Maria Tanase, Novartis

14:30 - 14:50      **Alk1:BMPRII agonism via bispecific clustering antibody for the treatment of HHT & PAH**

Patrick Andre, Diagonal Therapeutics

14:50 - 15:10      **Modulating TGF- $\beta$  signalling for pulmonary hypertension and HHT**

Nick Morrell, Interact Bio

15:10 - 15:30      **Q & A**

## **Developing therapeutic agents to target other genetically validated pathways**

Chairs: Brad Maron, University of Maryland and Mark Toshner, University of Cambridge

16:00 - 16:15      **Targeting ZIP12**

Rachel Gurrell, Apollo Therapeutics

16:15 - 16:30      **Sox17**

Chris Rhodes, Imperial College London

16:30 - 17:00      **Discussion:** What information should we be collecting from clinical trials to better inform drug development in this space?

---

17:00 - 18:30      **Networking reception**

---